Jin Yang Pharmaceutical Co., Ltd. (KOSDAQ:007370)

Jin Yang Pharmaceutical Income Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	116,974	113,332	93,708	76,264	62,839	49,525
Other Revenue	-0	-0	-	-0	-	-
Revenue	116,974	113,332	93,708	76,264	62,839	49,525
Revenue Growth (YoY)	18.58%	20.94%	22.87%	21.36%	26.88%	4.59%
Cost of Revenue	44,977	43,448	36,652	30,613	28,856	23,242
Gross Profit	71,998	69,884	57,056	45,651	33,984	26,282
Selling, General & Admin	60,456	59,052	46,381	33,981	27,965	24,282
Other Operating Expenses	273.09	205.11	170.02	139.73	146.93	108.97
Operating Expenses	58,651	58,175	48,374	34,513	27,020	22,022
Operating Income	13,347	11,708	8,682	11,138	6,964	4,261
Interest Expense	-2,157	-1,855	-1,374	-1,285	-208.28	-162.88
Interest & Investment Income	420	481.5	1,472	356.59	16.99	68.29
Currency Exchange Gain (Loss)	-2.71	-2.38	-1.69	3.53	-0.2	-0.03
Other Non Operating Income (Expenses)	1,669	2,439	937.36	839.11	3,913	387.95
EBT Excluding Unusual Items	13,276	12,771	9,716	11,053	10,685	4,554
Gain (Loss) on Sale of Investments	24,146	24,298	2,253	3,132	1,438	1,979
Gain (Loss) on Sale of Assets	-75.77	-77.14	0.86	24.9	9.53	0.6
Asset Writedown	-	-	-	325.53	-	-
Other Unusual Items	62.21	62.21	210.2	-	-	-
Pretax Income	37,408	37,054	12,180	14,535	12,132	6,533
Income Tax Expense	7,314	7,360	-160	2,227	2,594	1,305
Net Income	30,094	29,694	12,340	12,308	9,538	5,229
Net Income to Common	30,094	29,694	12,340	12,308	9,538	5,229
Net Income Growth	162.90%	140.63%	0.26%	29.05%	82.41%	217.50%
Shares Outstanding (Basic)	11	11	11	11	11	11
Shares Outstanding (Diluted)	12	12	12	13	11	11
Shares Change (YoY)	-5.33%	-1.17%	-7.18%	17.77%	2.12%	-
EPS (Basic)	2670.53	2692.30	1145.09	1114.86	853.30	467.79
EPS (Diluted)	2526.60	2408.01	988.98	915.61	835.60	467.79
EPS Growth	177.69%	143.48%	8.01%	9.57%	78.63%	217.50%
Free Cash Flow	-74,967	-77,268	7,851	4,230	-545.86	4,881
Free Cash Flow Per Share	-6293.97	-6265.96	629.22	314.65	-47.82	436.73
Gross Margin	61.55%	61.66%	60.89%	59.86%	54.08%	53.07%
Operating Margin	11.41%	10.33%	9.26%	14.61%	11.08%	8.60%
Profit Margin	25.73%	26.20%	13.17%	16.14%	15.18%	10.56%
Free Cash Flow Margin	-64.09%	-68.18%	8.38%	5.55%	-0.87%	9.86%
EBITDA	15,260	13,733	11,337	13,429	9,117	6,308
EBITDA Margin	13.05%	12.12%	12.10%	17.61%	14.51%	12.74%
D&A For EBITDA	1,913	2,024	2,655	2,291	2,154	2,048
EBIT	13,347	11,708	8,682	11,138	6,964	4,261
EBIT Margin	11.41%	10.33%	9.26%	14.61%	11.08%	8.60%
Effective Tax Rate	19.55%	19.86%	-	15.32%	21.38%	19.97%
Advertising Expenses	-	3,748	3,869	2,541	2,125	2,351

Updated Mar 1, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.